Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 10, 2023 16:01 ET
|
Erasca, Inc.
Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple...
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
June 22, 2023 16:01 ET
|
Erasca, Inc.
ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June 22, 2023 ...
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
June 05, 2023 16:01 ET
|
Erasca, Inc.
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK...
Erasca to Present at Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
May 31, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
May 25, 2023 17:00 ET
|
Erasca, Inc.
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation...
Erasca Further Strengthens Business Leadership with Two Key Promotions
May 16, 2023 08:00 ET
|
Erasca, Inc.
David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer Nik Chetwyn, Ph.D., previously Erasca’s...
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 15, 2023 16:01 ET
|
Erasca, Inc.
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1...
Erasca to Present at the Bank of America Securities 2023 Health Care Conference
May 02, 2023 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
May 01, 2023 08:00 ET
|
Erasca, Inc.
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients with recurrent GBM expected in H2 2023 ...